Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Accumulated Depreciation (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Accumulated Depreciation for 2 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation rose 35.47% to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 million, a 35.47% increase, with the full-year FY2025 number at $1.2 million, up 35.47% from a year prior.
  • Accumulated Depreciation was $1.2 million for Q4 2025 at Nuvation Bio, up from $874000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $1.2 million in Q4 2025 to a low of $874000.0 in Q4 2024.